

Alexander J Ambinder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7590971/publications.pdf>

Version: 2024-02-01

13
papers

138
citations

1684129
5
h-index

1372553
10
g-index

13
all docs

13
docs citations

13
times ranked

213
citing authors

#	ARTICLE	IF	CITATIONS
1	Potential targeting of FLT3 acute myeloid leukemia. <i>Haematologica</i> , 2021, 106, 671-681.	3.5	44
2	Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation. <i>Journal of Clinical Investigation</i> , 2019, 129, 4708-4723.	8.2	41
3	Autoimmune disease in CMML-the chicken or the egg?. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101136.	1.7	16
4	Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 259.e1-259.e11.	1.2	11
5	HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor age. <i>Blood Advances</i> , 2022, 6, 4335-4346.	5.2	9
6	Ibrutinib-associated hemophagocytic lymphohistiocytosis: A case series from Johns Hopkins. <i>American Journal of Hematology</i> , 2019, 94, E296-E299.	4.1	5
7	Carotidynia heralding the onset of acute leukemia. <i>American Journal of Medicine</i> , 2016, 129, e43-e45.	1.5	4
8	Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 260-269.	0.4	4
9	A Phase 1 Study of IRX195183, a RAR α -Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML. <i>Frontiers in Oncology</i> , 2020, 10, 587062.	2.8	3
10	Response Prediction to Isocitrate Dehydrogenase (IDH) Inhibitors in Patients with IDH1- or IDH2-Mutated Acute Myeloid Leukemia Using Clinical and Genomic Data. <i>Blood</i> , 2021, 138, 1285-1285.	1.4	1
11	β -2-Glycoprotein Antibodies Activate the Alternative Pathway of Complement in Antiphospholipid Antibody Syndrome. <i>Blood</i> , 2016, 128, 3818-3818.	1.4	0
12	Incorporating Gemtuzumab into the Treatment of Core Binding Factor Acute Myeloid Leukemia: A Single Center Experience. <i>Blood</i> , 2021, 138, 2337-2337.	1.4	0
13	Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab. <i>Blood</i> , 2021, 138, 1846-1846.	1.4	0